<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(9)</volume><submitter>Sia J</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Risk-reducing early-salpingectomy (RRES) and delayed oophorectomy (DO) is a novel 2-stage alternative prevention strategy to risk-reducing salpingo-oophorectomy (RRSO) that avoids detrimental consequences of premature menopause. However, direct data on the clinical effectiveness for ovarian cancer (OC) risk reduction are lacking.&lt;h4>Objective&lt;/h4>To explore how to define clinical effectiveness from prospective cohort studies using the estimand framework and sample size requirements.&lt;h4>Design, setting, and participants&lt;/h4>In this comparative effectiveness research study, estimand and analysis options were considered to evaluate the clinical effectiveness of RRES with DO by extending the UK PROTECTOR cohort study, a multicenter, prospective, observational, national cohor</pubmed_abstract><journal>JAMA network open</journal><pagination>e2532195</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12441877</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer.</pubmed_title><pmcid>PMC12441877</pmcid><pubmed_authors>Ray I</pubmed_authors><pubmed_authors>Crosbie E</pubmed_authors><pubmed_authors>Taylor S</pubmed_authors><pubmed_authors>Povolotskaya N</pubmed_authors><pubmed_authors>Hamed H</pubmed_authors><pubmed_authors>Ahmed M</pubmed_authors><pubmed_authors>Baxter K</pubmed_authors><pubmed_authors>Chattopadhyay S</pubmed_authors><pubmed_authors>Oxley S</pubmed_authors><pubmed_authors>Duncan T</pubmed_authors><pubmed_authors>Elboraei R</pubmed_authors><pubmed_authors>Mackintosh M</pubmed_authors><pubmed_authors>Matthews N</pubmed_authors><pubmed_authors>Lane EF</pubmed_authors><pubmed_authors>Hanson H</pubmed_authors><pubmed_authors>Newton C</pubmed_authors><pubmed_authors>Willett M</pubmed_authors><pubmed_authors>Khaing TT</pubmed_authors><pubmed_authors>Reig G</pubmed_authors><pubmed_authors>Devaja O</pubmed_authors><pubmed_authors>Chalhoub T</pubmed_authors><pubmed_authors>Dalton J</pubmed_authors><pubmed_authors>Sundar S</pubmed_authors><pubmed_authors>Gurumurthy M</pubmed_authors><pubmed_authors>PROTECTOR team</pubmed_authors><pubmed_authors>Bryson G</pubmed_authors><pubmed_authors>Ohwo V</pubmed_authors><pubmed_authors>Legood R</pubmed_authors><pubmed_authors>Wei X</pubmed_authors><pubmed_authors>Harley I</pubmed_authors><pubmed_authors>Borley J</pubmed_authors><pubmed_authors>Ghaem-Maghami S</pubmed_authors><pubmed_authors>Ragupathy K</pubmed_authors><pubmed_authors>Casey L</pubmed_authors><pubmed_authors>De Souza B</pubmed_authors><pubmed_authors>Kalra A</pubmed_authors><pubmed_authors>Singh A</pubmed_authors><pubmed_authors>Faruqi A</pubmed_authors><pubmed_authors>Van Seters M</pubmed_authors><pubmed_authors>Edey K</pubmed_authors><pubmed_authors>Idahl A</pubmed_authors><pubmed_authors>Sideris M</pubmed_authors><pubmed_authors>Side L</pubmed_authors><pubmed_authors>Kamran A</pubmed_authors><pubmed_authors>Rao S</pubmed_authors><pubmed_authors>Piletska N</pubmed_authors><pubmed_authors>Iyer R</pubmed_authors><pubmed_authors>Prasad M</pubmed_authors><pubmed_authors>Saridogan E</pubmed_authors><pubmed_authors>McDermott J</pubmed_authors><pubmed_authors>Misiura H</pubmed_authors><pubmed_authors>Brady A</pubmed_authors><pubmed_authors>Fraser H</pubmed_authors><pubmed_authors>Arora R</pubmed_authors><pubmed_authors>Sasieni P</pubmed_authors><pubmed_authors>Sharma A</pubmed_authors><pubmed_authors>Ganesan R</pubmed_authors><pubmed_authors>Kaushik S</pubmed_authors><pubmed_authors>Ganesan S</pubmed_authors><pubmed_authors>Evans DG</pubmed_authors><pubmed_authors>Singh N</pubmed_authors><pubmed_authors>Barker V</pubmed_authors><pubmed_authors>Manchanda R</pubmed_authors><pubmed_authors>Kohut K</pubmed_authors><pubmed_authors>Fierheller CT</pubmed_authors><pubmed_authors>Kodiathodi S</pubmed_authors><pubmed_authors>Fegan S</pubmed_authors><pubmed_authors>Hutson R</pubmed_authors><pubmed_authors>Oktaba M</pubmed_authors><pubmed_authors>Park C</pubmed_authors><pubmed_authors>Bolton H</pubmed_authors><pubmed_authors>Snape K</pubmed_authors><pubmed_authors>Tryczynska M</pubmed_authors><pubmed_authors>Tailor A</pubmed_authors><pubmed_authors>Alazzani H</pubmed_authors><pubmed_authors>Ryan N</pubmed_authors><pubmed_authors>McArdle G</pubmed_authors><pubmed_authors>Balega J</pubmed_authors><pubmed_authors>Gnanachandran C</pubmed_authors><pubmed_authors>Mehra G</pubmed_authors><pubmed_authors>Menon U</pubmed_authors><pubmed_authors>Abdelaziz M</pubmed_authors><pubmed_authors>McCluggage WG</pubmed_authors><pubmed_authors>Sia J</pubmed_authors><pubmed_authors>Rowlands G</pubmed_authors><pubmed_authors>Phillips A</pubmed_authors><pubmed_authors>Sengupta P</pubmed_authors><pubmed_authors>Abdul B</pubmed_authors><pubmed_authors>Williamson K</pubmed_authors><pubmed_authors>O'Donnell R</pubmed_authors><pubmed_authors>Peevor R</pubmed_authors><pubmed_authors>Rosenthal A</pubmed_authors><pubmed_authors>Marks M</pubmed_authors><pubmed_authors>Sassarini J</pubmed_authors><pubmed_authors>Brentnall A</pubmed_authors><pubmed_authors>Cameron I</pubmed_authors><pubmed_authors>Pilkington T</pubmed_authors><pubmed_authors>Doh H</pubmed_authors><pubmed_authors>Mansour L</pubmed_authors><pubmed_authors>Trevisan G</pubmed_authors><pubmed_authors>Zulfiqar N</pubmed_authors><pubmed_authors>Deshmukh P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer.</name><description>&lt;h4>Importance&lt;/h4>Risk-reducing early-salpingectomy (RRES) and delayed oophorectomy (DO) is a novel 2-stage alternative prevention strategy to risk-reducing salpingo-oophorectomy (RRSO) that avoids detrimental consequences of premature menopause. However, direct data on the clinical effectiveness for ovarian cancer (OC) risk reduction are lacking.&lt;h4>Objective&lt;/h4>To explore how to define clinical effectiveness from prospective cohort studies using the estimand framework and sample size requirements.&lt;h4>Design, setting, and participants&lt;/h4>In this comparative effectiveness research study, estimand and analysis options were considered to evaluate the clinical effectiveness of RRES with DO by extending the UK PROTECTOR cohort study, a multicenter, prospective, observational, national cohor</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-07-15T06:51:33.026Z</modification><creation>2026-06-30T03:27:09.062Z</creation></dates><accession>S-EPMC12441877</accession><cross_references><pubmed>40956577</pubmed><doi>10.1001/jamanetworkopen.2025.32195</doi></cross_references></HashMap>